Published in N Engl J Med on December 05, 2002
The global programme to eliminate lymphatic filariasis: health impact after 8 years. PLoS Negl Trop Dis (2008) 4.36
Use of high-dose, twice-yearly albendazole and ivermectin to suppress Wuchereria bancrofti microfilarial levels. Clin Infect Dis (2010) 2.23
The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000-2007). PLoS Negl Trop Dis (2010) 1.81
The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea. PLoS Negl Trop Dis (2008) 1.74
Determinants of success in national programs to eliminate lymphatic filariasis: a perspective identifying essential elements and research needs. Am J Trop Med Hyg (2008) 1.70
Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. PLoS Negl Trop Dis (2014) 1.68
Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature. Filaria J (2007) 1.59
Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog (2006) 1.57
Epidemiological and entomological evaluations after six years or more of mass drug administration for lymphatic filariasis elimination in Nigeria. PLoS Negl Trop Dis (2011) 1.54
Lymphatic Filariasis (Elephantiasis) Elimination: A public health success and development opportunity. Filaria J (2003) 1.51
Insecticidal bed nets and filariasis transmission in Papua New Guinea. N Engl J Med (2013) 1.48
A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis. PLoS Negl Trop Dis (2013) 1.42
A critical appraisal of molecular xenomonitoring as a tool for assessing progress toward elimination of Lymphatic Filariasis. Am J Trop Med Hyg (2007) 1.39
Geographic and ecologic heterogeneity in elimination thresholds for the major vector-borne helminthic disease, lymphatic filariasis. BMC Biol (2010) 1.38
Endpoints for lymphatic filariasis programs. Emerg Infect Dis (2007) 1.32
Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation. Am J Trop Med Hyg (2008) 1.25
Vector control complements mass drug administration against bancroftian filariasis in Tirukoilur, India. Bull World Health Organ (2007) 1.22
Defining the cost of the Egyptian lymphatic filariasis elimination programme. Filaria J (2005) 1.21
The impact of mass drug administration and long-lasting insecticidal net distribution on Wuchereria bancrofti infection in humans and mosquitoes: an observational study in northern Uganda. Parasit Vectors (2011) 1.18
Feasibility and effectiveness of basic lymphedema management in Leogane, Haiti, an area endemic for bancroftian filariasis. PLoS Negl Trop Dis (2010) 1.10
Global eradication of lymphatic filariasis: the value of chronic disease control in parasite elimination programmes. PLoS One (2008) 1.08
Mathematical models for lymphatic filariasis transmission and control: Challenges and prospects. Parasit Vectors (2008) 1.06
Assessing progress in reducing the at-risk population after 13 years of the global programme to eliminate lymphatic filariasis. PLoS Negl Trop Dis (2014) 1.06
Marriage, sex, and hydrocele: an ethnographic study on the effect of filarial hydrocele on conjugal life and marriageability from Orissa, India. PLoS Negl Trop Dis (2009) 1.00
Studies of Anopheles gambiae s.l (Diptera: Culicidae) exhibiting different vectorial capacities in lymphatic filariasis transmission in the Gomoa district, Ghana. Parasit Vectors (2010) 0.99
Mosquito-parasite interactions can shape filariasis transmission dynamics and impact elimination programs. PLoS Negl Trop Dis (2013) 0.95
Molecular-based assay for simultaneous detection of four Plasmodium spp. and Wuchereria bancrofti infections. Am J Trop Med Hyg (2010) 0.94
Impact of two rounds of mass drug administration using diethylcarbamazine combined with albendazole on the prevalence of Brugia timori and of intestinal helminths on Alor Island, Indonesia. Filaria J (2005) 0.92
The impact of a filariasis control program on Lihir Island, Papua New Guinea. PLoS Negl Trop Dis (2011) 0.90
Major progress toward eliminating lymphatic filariasis. N Engl J Med (2002) 0.88
Current evidence on the use of antifilarial agents in the management of bancroftian filariasis. J Trop Med (2010) 0.88
Impact of a community-based lymphedema management program on episodes of Adenolymphangitis (ADLA) and lymphedema progression--Odisha State, India. PLoS Negl Trop Dis (2014) 0.87
Bayesian calibration of simulation models for supporting management of the elimination of the macroparasitic disease, Lymphatic Filariasis. Parasit Vectors (2015) 0.86
Reduction in acute filariasis morbidity during a mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea. PLoS Negl Trop Dis (2011) 0.86
Sequential modelling of the effects of mass drug treatments on anopheline-mediated lymphatic filariasis infection in Papua New Guinea. PLoS One (2013) 0.85
Mass treatment of filariasis in New Guinea. N Engl J Med (2003) 0.84
Heterogeneous dynamics, robustness/fragility trade-offs, and the eradication of the macroparasitic disease, lymphatic filariasis. BMC Med (2016) 0.81
Lymphatic filariasis in Papua New Guinea: distribution at district level and impact of mass drug administration, 1980 to 2011. Parasit Vectors (2013) 0.81
Impact of basic lymphedema management and antifilarial treatment on acute dermatolymphangioadenitis episodes and filarial antigenaemia. J Glob Infect Dis (2011) 0.80
The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000-2014). Infect Dis Poverty (2016) 0.80
Molecular epidemiology, phylogeny and evolution of the filarial nematode Wuchereria bancrofti. Infect Genet Evol (2014) 0.79
A longitudinal analysis of the effect of mass drug administration on acute inflammatory episodes and disease progression in lymphedema patients in Leogane, Haiti. Am J Trop Med Hyg (2013) 0.78
Population genetics of the filarial worm wuchereria bancrofti in a post-treatment region of Papua New Guinea: insights into diversity and life history. PLoS Negl Trop Dis (2013) 0.78
Mass treatment of filariasis in New Guinea. N Engl J Med (2003) 0.75
Changes in Antibody Levels during and following an Episode of Acute Adenolymphangitis (ADL) among Lymphedema Patients in Léogâne, Haiti. PLoS One (2015) 0.75
Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet (2005) 9.45
Kuru in the 21st century--an acquired human prion disease with very long incubation periods. Lancet (2006) 5.42
Mass treatment with single-dose azithromycin for trachoma. N Engl J Med (2004) 5.30
Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med (2008) 5.29
A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis (2002) 4.14
Strategies for control of trachoma: observational study with quantitative PCR. Lancet (2003) 3.40
Plasmodium falciparum erythrocyte invasion through glycophorin C and selection for Gerbich negativity in human populations. Nat Med (2002) 3.29
Two doses of azithromycin to eliminate trachoma in a Tanzanian community. N Engl J Med (2008) 2.71
Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. Lancet (2005) 2.50
Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in Gambian villages. Invest Ophthalmol Vis Sci (2003) 2.20
Mathematical modelling and the control of lymphatic filariasis. Lancet Infect Dis (2004) 2.13
Why do we need to know more about mixed Plasmodium species infections in humans? Trends Parasitol (2004) 1.98
Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol (2009) 1.94
Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. Am J Trop Med Hyg (2006) 1.93
Benefits of routine immunizations on childhood survival in Tari, Southern Highlands Province, Papua New Guinea. Int J Epidemiol (2004) 1.92
Can prenatal malaria exposure produce an immune tolerant phenotype? A prospective birth cohort study in Kenya. PLoS Med (2009) 1.87
The role of animal models for research on severe malaria. PLoS Pathog (2012) 1.76
The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea. PLoS Negl Trop Dis (2008) 1.74
Malaria infections are randomly distributed in diverse holoendemic areas of Papua New Guinea. Am J Trop Med Hyg (2002) 1.73
Determinants of success in national programs to eliminate lymphatic filariasis: a perspective identifying essential elements and research needs. Am J Trop Med Hyg (2008) 1.70
Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. Am J Trop Med Hyg (2005) 1.70
Profound and sustained reduction in Chlamydia trachomatis in The Gambia: a five-year longitudinal study of trachoma endemic communities. PLoS Negl Trop Dis (2010) 1.67
The incubation period of kuru. Epidemiology (2002) 1.56
A novel protective prion protein variant that colocalizes with kuru exposure. N Engl J Med (2009) 1.53
Age-acquired immunity to a Plasmodium vivax invasion ligand, the duffy binding protein. J Infect Dis (2002) 1.53
Prevention of allergic transfusion reactions to platelets and red blood cells through plasma reduction. Transfusion (2011) 1.51
Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother (2008) 1.50
Insecticidal bed nets and filariasis transmission in Papua New Guinea. N Engl J Med (2013) 1.48
Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults. PLoS One (2008) 1.46
The long-term natural history of trachomatous trichiasis in the Gambia. Invest Ophthalmol Vis Sci (2006) 1.46
Reduced Plasmodium vivax erythrocyte infection in PNG Duffy-negative heterozygotes. PLoS One (2007) 1.45
Innate immune responses to endosymbiotic Wolbachia bacteria in Brugia malayi and Onchocerca volvulus are dependent on TLR2, TLR6, MyD88, and Mal, but not TLR4, TRIF, or TRAM. J Immunol (2007) 1.44
Exposure to holoendemic malaria results in suppression of Epstein-Barr virus-specific T cell immunosurveillance in Kenyan children. J Infect Dis (2007) 1.39
Mathematical models and lymphatic filariasis control: endpoints and optimal interventions. Trends Parasitol (2006) 1.39
Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine (2003) 1.39
Quality of life and social support among patients receiving antiretroviral therapy in Western Uganda. AIDS Care (2009) 1.37
The Global Trachoma Mapping Project: Methodology of a 34-Country Population-Based Study. Ophthalmic Epidemiol (2015) 1.36
Acquired immune responses to Plasmodium falciparum merozoite surface protein-1 in the human fetus. J Immunol (2002) 1.32
Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. J Infect Dis (2008) 1.32
Prenatal T cell immunity to Wuchereria bancrofti and its effect on filarial immunity and infection susceptibility during childhood. J Infect Dis (2006) 1.31
Antibodies to the Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adhesive protein, and liver-stage antigen 1 vary by ages of subjects and by season in a highland area of Kenya. Infect Immun (2003) 1.29
Polymerase chain reaction diagnosis and the changing pattern of vector ecology and malaria transmission dynamics in papua new Guinea. Am J Trop Med Hyg (2004) 1.28
Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria. Infect Immun (2004) 1.27
Distinct Th1- and Th2-Type prenatal cytokine responses to Plasmodium falciparum erythrocyte invasion ligands. Infect Immun (2005) 1.26
Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation. Am J Trop Med Hyg (2008) 1.25
Age-dependent cellular immune responses to Plasmodium vivax Duffy binding protein in humans. J Immunol (2002) 1.22
Epitope-specific humoral immunity to Plasmodium vivax Duffy binding protein. Infect Immun (2003) 1.21
Mathematical models and lymphatic filariasis control: monitoring and evaluating interventions. Trends Parasitol (2006) 1.20
Strain-specific humoral response to a polymorphic malaria vaccine. Infect Immun (2004) 1.18
HECTD2 is associated with susceptibility to mouse and human prion disease. PLoS Genet (2009) 1.18
Adherence and treatment response among HIV-1-infected adults receiving antiretroviral therapy in a rural government hospital in Southwestern Uganda. J Int Assoc Physicians AIDS Care (Chic) (2009) 1.18
Low prevalence of antibodies to preerythrocytic but not blood-stage Plasmodium falciparum antigens in an area of unstable malaria transmission compared to prevalence in an area of stable malaria transmission. Infect Immun (2008) 1.17
Increased microerythrocyte count in homozygous alpha(+)-thalassaemia contributes to protection against severe malarial anaemia. PLoS Med (2008) 1.17
Human immunodeficiency virus and other sexually transmitted infections among female sex workers in two major cities in Papua New Guinea. Sex Transm Dis (2002) 1.15
Mass chemotherapy options to control lymphatic filariasis: a systematic review. Lancet Infect Dis (2005) 1.13
Influence of maternal filariasis on childhood infection and immunity to Wuchereria bancrofti in Kenya. Infect Immun (2003) 1.12
Genome-wide association study in multiple human prion diseases suggests genetic risk factors additional to PRNP. Hum Mol Genet (2011) 1.12
A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea. Philos Trans R Soc Lond B Biol Sci (2008) 1.10
Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria. Antimicrob Agents Chemother (2004) 1.10
Three different Plasmodium species show similar patterns of clinical tolerance of malaria infection. Malar J (2009) 1.09
Global eradication of lymphatic filariasis: the value of chronic disease control in parasite elimination programmes. PLoS One (2008) 1.08
Prenatal malaria immune experience affects acquisition of Plasmodium falciparum merozoite surface protein-1 invasion inhibitory antibodies during infancy. J Immunol (2006) 1.07
Parasitological and clinical efficacy of standard treatment regimens against Plasmodium falciparum, P. vivax and P. malariae in Papua New Guinea. P N G Med J (2007) 1.05
A polymerase chain reaction/ligase detection reaction fluorescent microsphere assay to determine Plasmodium falciparum MSP-119 haplotypes. Am J Trop Med Hyg (2007) 1.05
Spatial variation of Anopheles-transmitted Wuchereria bancrofti and Plasmodium falciparum infection densities in Papua New Guinea. Filaria J (2003) 1.04
Lymphocyte proliferation and antibody responses to Plasmodium falciparum liver-stage antigen-1 in a highland area of Kenya with seasonal variation in malaria transmission. Am J Trop Med Hyg (2002) 1.04
Glycophorin C (Gerbich antigen blood group) and band 3 polymorphisms in two malaria holoendemic regions of Papua New Guinea. Am J Hematol (2004) 1.03
Lymphatic filariasis in Papua New Guinea: prospects for elimination. Med Microbiol Immunol (2002) 1.03
The complete mitochondrial genome sequence of the filarial nematode Wuchereria bancrofti from three geographic isolates provides evidence of complex demographic history. Mol Biochem Parasitol (2012) 1.03
Stability of interferon-gamma and interleukin-10 responses to Plasmodium falciparum liver stage antigen-1 and thrombospondin-related adhesive protein in residents of a malaria holoendemic area. Am J Trop Med Hyg (2006) 1.01
Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria. Pediatr Infect Dis J (2011) 1.01
TLR9 polymorphisms are associated with altered IFN-gamma levels in children with cerebral malaria. Am J Trop Med Hyg (2010) 1.00
Temporal stability of naturally acquired immunity to Merozoite Surface Protein-1 in Kenyan adults. Malar J (2009) 1.00
Age-related differences in naturally acquired T cell memory to Plasmodium falciparum merozoite surface protein 1. PLoS One (2011) 1.00
Antibodies to Plasmodium falciparum antigens vary by age and antigen in children in a malaria-holoendemic area of Kenya. Pediatr Infect Dis J (2005) 0.99
Humoral and cellular immunity to Plasmodium falciparum merozoite surface protein 1 and protection from infection with blood-stage parasites. J Infect Dis (2013) 0.99
The acute phase response in children with mild and severe malaria in Papua New Guinea. Trans R Soc Trop Med Hyg (2009) 0.98
Lean tissue mass wasting is associated with increased risk of mortality among women with pulmonary tuberculosis in urban Uganda. Ann Epidemiol (2012) 0.97
The dynamics of naturally acquired immunity to Plasmodium falciparum infection. PLoS Comput Biol (2012) 0.97
Class II MHC antigen presentation defect in neonatal monocytes is not correlated with decreased MHC-II expression. Cell Immunol (2007) 0.97
Operational evaluation of the use of photographs for grading active trachoma. Am J Trop Med Hyg (2006) 0.97
Studies of maternal immunisation with pneumococcal polysaccharide vaccine in Papua New Guinea. Vaccine (2003) 0.94
Safety and therapeutic efficacy of artesunate suppositories for treatment of malaria in children in Papua New Guinea. Pediatr Infect Dis J (2003) 0.94
Molecular-based assay for simultaneous detection of four Plasmodium spp. and Wuchereria bancrofti infections. Am J Trop Med Hyg (2010) 0.94